Company* (Country; Symbol) |
Company (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
I. MODIFIED AGREEMENTS | |||
APRIL | |||
Alseres Pharmaceuticals Inc. (ALSE) | BioAxone Therapeutic Inc.* (Canada) | Amended agreement for Cethrin and Rho inhibitor technology | If Alseres fails to sub-license its rights under the Cethrin license within a specified time period, the company retains a right to receive a smaller portion of any license revenue that BioAxone generates after the Cethrin license terminates (4/30) |
Cangene Corp. (Canada; TSX:CNJ) | Apotex Group* (Canada) | Revised deal giving Cangene the rights to commercialize its pipeline of recombinant products | The two parties will share the right to market Leucotropin and Accretropin, and Cangene's royalty on Ferriprox (deferiprone) will be phased out over three years (4/16) |
MAY | |||
Argenta Discovery Ltd.* | Genentech Inc. | Extended drug discovery agreement for two years | The agreement covers a number of drug discovery programs that use Argenta's computer-aided drug design, medicinal chemistry and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech (5/20) |
II. TERMINATED AGREEMENTS | |||
XenoPort Inc. (XNPT) | Xanodyne Pharmaceuticals Inc.* | Terminated partnership for the development of XP21510, a preclinical drug for menorrhagia | XenoPort had thus far received $12M up front and $1M out of a potential $129M in milestone payments; rights to XP21510 will return to XenoPort (4/2) |
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market.TSX = Toronto Stock Exchange; SWX = Swiss Stock Exchange. | |||